Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma.
about
An expression signature of syndecan-1 (CD138), E-cadherin and c-met is associated with factors of angiogenesis and lymphangiogenesis in ductal breast carcinoma in situEGFR/Met association regulates EGFR TKI resistance in breast cancerLRIG1 is a novel negative regulator of the Met receptor and opposes Met and Her2 synergyMET deregulation in breast cancerAbl Kinases Regulate HGF/Met Signaling Required for Epithelial Cell Scattering, Tubulogenesis and MotilityMet kinetic signature derived from the response to HGF/SF in a cellular model predicts breast cancer patient survivalThe clinical and functional significance of c-Met in breast cancer: a reviewPrognostic significance of c-Met in breast cancer: a meta-analysis of 6010 casesMet receptor tyrosine kinase signals through a cortactin-Gab1 scaffold complex, to mediate invadopodiaCrk adapter proteins promote an epithelial-mesenchymal-like transition and are required for HGF-mediated cell spreading and breakdown of epithelial adherens junctions.Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cellsCyclooxygenase-2 is a novel transcriptional target of the nuclear EGFR-STAT3 and EGFRvIII-STAT3 signaling axesGermline met mutations in mice reveal mutation- and background-associated differences in tumor profiles.EGFR and EGFRvIII interact with PUMA to inhibit mitochondrial translocalization of PUMA and PUMA-mediated apoptosis independent of EGFR kinase activity.Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models.MET and MYC cooperate in mammary tumorigenesis.The Met oncogene and basal-like breast cancer: another culprit to watch out for?Development of c-MET pathway inhibitors.Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastasesCo-expression of MET and CD47 is a novel prognosticator for survival of luminal breast cancer patientsSRC-3 coactivator regulates cell resistance to cytotoxic stress via TRAF4-mediated p53 destabilization.The HGF receptor c-Met is overexpressed in esophageal adenocarcinoma.Central role of cellular senescence in TSLP-induced airway remodeling in asthma.The role of receptor tyrosine kinase inhibition in treating gastrointestinal malignancy.c-Met in esophageal squamous cell carcinoma: an independent prognostic factor and potential therapeutic targetAn aberrant nuclear localization of E-cadherin is a potent inhibitor of Wnt/β-catenin-elicited promotion of the cancer stem cell phenotype.MET and PTEN gene copy numbers and Ki-67 protein expression associate with pathologic complete response in ERBB2-positive breast carcinoma patients treated with neoadjuvant trastuzumab-based therapy.Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma.Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancerTBX2 expression is regulated by PAX3 in the melanocyte lineagePolarized cell migration induces cancer type-specific CD133/integrin/Src/Akt/GSK3β/β-catenin signaling required for maintenance of cancer stem cell properties.Targeting matriptase in breast cancer abrogates tumour progression via impairment of stromal-epithelial growth factor signalling.c-Met overexpression in inflammatory breast carcinomas: automated quantification on tissue microarraysHigh MET expression is an adverse prognostic factor in patients with triple-negative breast cancerMet synergizes with p53 loss to induce mammary tumors that possess features of claudin-low breast cancer.c-Met Mutational Analysis in the Sema and Juxtamembrane Domains in Small-Cell-Lung-Cancer.An antimetastatic role for decorin in breast cancer.Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expressioncMET and phospho-cMET protein levels in breast cancers and survival outcomes.Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer.
P2860
Q21195234-EF033E48-F2E2-40FB-AADE-3A6DE71C5631Q24338635-0371E1FF-414C-437E-87E5-2A74A6291EE1Q24681561-B831E524-DAF5-4210-A1C9-8012B8B758BBQ26781054-CAAF3F15-6D72-44CE-84FB-C74409A71FD0Q27308835-419BE064-5069-4E4E-8AB5-943EC8FD342BQ27316936-99F42156-875B-4E55-9764-622956C52585Q28081415-2637DB42-3BA6-4321-B589-3E3FE7B8D087Q28087523-F2E5A8CB-F995-4561-BFC1-EFAA270509DEQ30010161-0F623363-6AE2-4ACE-9FEF-BDF0AD861B45Q30165423-1B49E8BA-F9D9-4D73-9567-55AF235889B2Q30415408-B0BAE8D7-80F4-493A-BAC3-9B963A9DD16EQ33669979-896BCAC9-CAAA-4D29-AEF1-78EF70502C68Q33737789-E59ACA74-B22C-4477-B810-1DE3ED7D76C6Q33872371-E4F8DE6C-1802-42AF-98D2-37AB53CB6ACFQ33880064-DF673F45-6238-49C4-A5D9-7371486878F7Q33926873-BC1686FA-0735-4EAD-9D09-A9212027E22EQ34173500-70265EAB-69AE-4F84-BC77-B7604E6CAC2FQ34198905-38108114-5B1A-476A-99B9-2FDDDB0DE6FCQ34245828-5D24AD18-65C3-42D7-BD4C-C54226BECA16Q34483478-5BA952C8-DD4C-491F-8BDD-1333B8A4F280Q34579190-5FF046C6-BE47-41E5-BF84-34EFCB9A6F96Q34724977-716A7F64-C79E-4750-B5F3-86838B097D03Q35027776-C7BF197B-3D7F-43FF-A2C0-7CDD3EEEBE5BQ35094666-81CB7696-D7A3-4A45-9A06-99871E40F9EEQ35650167-B0C60675-051F-4B07-9D2E-3719F5D84A4CQ35818227-0E6EAEDF-5D39-4DE5-87B0-1F1CF2B1EED0Q36117367-31116991-4803-4B35-B5C4-8FA72653A880Q36132720-3288A754-B123-4788-9694-08EFB72BA6C7Q36169304-040D1AC2-B2CF-4C94-8DAC-45D11919850CQ36481040-6C4A55FB-E454-4A01-BECA-3AB967F4B5B2Q36545955-B47B4627-0E5D-460A-9867-F0B8FA5AD450Q36567735-E81A201B-DF2F-4D3F-80F2-E53F47BA2786Q36609706-E53CF0E6-7075-4790-ABD4-1FFE2135DDADQ36746729-1D3BA2E6-32E0-424C-94E1-ABC725AF965FQ36747465-14D5EAEF-AB7E-4F76-A44D-09165F8CB1DEQ36812161-915B1DE9-6B48-4789-95C0-4669256F61F4Q36855729-AF63C428-9DE2-4BCB-BB0E-AE72AE966AD4Q36945006-2B40C7D6-B9EA-4D4F-B301-7A100799AE47Q37290053-50C7A0C4-A630-4C9D-BA5D-5EB6149822C3Q37293205-6E86775A-3DEB-41DC-BC23-3B4C463DE5CD
P2860
Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Met expression is associated w ...... ode negative breast carcinoma.
@en
type
label
Met expression is associated w ...... ode negative breast carcinoma.
@en
prefLabel
Met expression is associated w ...... ode negative breast carcinoma.
@en
P2093
P2860
P1433
P1476
Met expression is associated w ...... ode negative breast carcinoma.
@en
P2093
P2860
P304
P356
10.1002/(SICI)1097-0142(19991201)86:11<2259::AID-CNCR13>3.0.CO;2-2
P407
P577
1999-12-01T00:00:00Z